China's Top Drug CDMO May be a Big Winner as Supplier for Pfizer's Covid Pill

若离

若离

· 11月18日

Asymchem signed supply contracts valued a total of $480 million with a major US company, which is said to be Pfizer that just sought authorization for a Covid-19 oral antiviral drug with data showed an 89% reduction in risk of hospitalization or death.

BEIJING, November 17 (TMTPOST)— Thanks to a large order that signaled the powerful potential as a supplier for Pfizer’s promising Covid treatment, Shenzhen-listed shares of Asymchem Laboratories, a leading Contract Development and Manufacturing Organization (CDMO) that provides integrated solutions to pharmaceutical and biotech companies across the world, rose by their 10% daily limit in early trading and settled 7% higher on Wednesday.  

Source: Visual China

In a statement released late Tuesday, Asymchem said it has being offering CDMO services for a new small-molecule chemical drug developed by a major U.S. pharmaceutical company and two wholly-owned subsidiaries Asymchem,Inc. and Jilin Asymchem Pharmaceuticals Co., Ltd recently have signed new supply contracts from 2021 to 2022 for the new drug, so the total contract value amounted to US$480.94 million as of the signing day. In order to protect commercial secrets involved in the contract, Asymchem didn’t disclose its counterparty’s name but said it was the biggest client last year as revenue from services for it recorded RMB638 million, representing 20.25% of the company’s annual revenue. Many Chinese investment researchers and media outlets including The Economic Observer suspected the big client was Pfizer and the new drug Asymchem was working for was Paxlovid, a Covid-19 oral antiviral candidate Pfizer just applied for Emergency Use Authorization (EUA) with the the U.S. Food and Drug Administration (FDA) on Wednesday. Earlier this month, Pfizer revealed the clinical data from an interim analysis of the Phase 2/3 EPIC-HR study, which demonstrated an 89% reduction in risk of hospitalization or death compared to placebo in non-hospitalized high-risk adults with COVID-19, if Paxlovid taken in combination with a HIV drug Ritonavir within three days of onset of symptoms. Based on contract terms and the projected mass production timetable of Paxlovid, Asymchem’s latest order is expected to enter in commercial production in the fourth quarter and most of contract value would be recognized as revenue in 2022, a significant boost for the company’s performance.

Asymchem ranked the fifth in the global drug substance CDMO market and the first in the China-based commercial stage chemical drug CDMO market in terms of revenue in 2020, according to Frost & Sullivan. The stock jumped almost 50% year to date and up more than 10% this month alone as of Wednesday.

本文系作者若离授权钛媒体发表,并经钛媒体编辑,转载请注明出处、作者和本文链接
本文观点仅代表作者本人,钛媒体平台仅对用户提供信息及决策参考,本文不构成投资建议。
想和千万钛媒体用户分享你的新奇观点和发现,点击这里投稿 。创业或融资寻求报道,点击这里

敬原创,有钛度,得赞赏

”支持原创,赞赏一下“
小团子_TE7FCjF 钛粉57559 钛粉27830 钛粉46586 钛粉94275 关东流匪
493人已赞赏 >
493换成打赏总人数493人赞赏钛媒体文章
关闭弹窗

挺钛度,加点码!

  • ¥ 5
  • ¥ 10
  • ¥ 20
  • ¥ 50
  • ¥ 100

支付方式

确认支付
关闭弹窗

支付

支付金额:¥6

关闭弹窗
sussess

赞赏金额:¥ 6

赞赏时间:2020.02.11 17:32

关闭弹窗 关闭弹窗

注册邮箱未验证

我们已向下方邮箱发送了验证邮件,请查收并按提示验证您的邮箱。

如果您没有收到邮件,请留意垃圾邮件箱。

更换邮箱

您当前使用的邮箱可能无法接收验证邮件,建议您更换邮箱

账号合并

经检测,你是“钛媒体”和“商业价值”的注册用户。现在,我们对两个产品因进行整合,需要您选择一个账号用来登录。无论您选择哪个账号,两个账号的原有信息都会合并在一起。对于给您造成的不便,我们深感歉意。